publication . Article . 2016

Repurposing drugs for treatment of tuberculosis (TB): a role for non-steroidal anti-inflammatory drugs.

Maitra, Arundhati; Bhakta, Sanjib; Evangelopoulos, Dimitrios;
Open Access English
  • Published: 10 Jun 2016
  • Publisher: Oxford Journals
  • Country: United Kingdom
Introduction \ud The number of cases of drug-resistant Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), has risen rapidly in recent years. This has led to the resurgence in repurposing existing drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), for anti-TB treatment. \ud Sources of data\ud Evidence from novel drug screening in vitro, in vivo, pharmacokinetic/pharmacodynamics analyses and clinical trials has been used for the preparation of this systematic review of the potential of NSAIDs for use as an adjunct in new TB chemotherapies. \ud Areas of agreement\ud Certain NSAIDs have demonstrated inhibitory properties towards active...
free text keywords: bcs
Funded by
  • Funder: Wellcome Trust (WT)
17 references, page 1 of 2

Organization WH. Global tuberculosis report 2015. 2015

Burman WJ. Rip Van Winkle Wakes Up: Development of Tuberculosis Treatment in the 21st Century. Clinical Infectious Diseases 2010; 50: S165-S172

Maitra A, Bhakta S. TB Summit 2014: prevention, diagnosis, and treatment of tuberculosis-a meeting report of a Euroscicon conference. Virulence 2014; 5: 638-44 Maitra A, Danquah CA, Scotti F et al. Tackling tuberculosis: Insights from an international TB Summit in London. Virulence 2015; 6: 581-92 [OpenAIRE]

Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007; 6: 29-40 Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006; 25: 420-8

Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3: 673-83

Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013; 12: 388-404 [OpenAIRE]

Languillon J. The effects ot thalidomide on leprosy reaction. International Journal of Leprosy 1971; 39: 590-592

Schoeman JF, Fieggen G, Seller N, Mendelson M, Hartzenberg B. Intractable Intracranial Tuberculous Infection Responsive to Thalidomide: Report of Four Cases. Journal of Child Neurology 2006; 21: 301-308

Oprea TI, Mestres J. Drug repurposing: far beyond new targets for old drugs. AAPS J 2012; 14: 759-63 [OpenAIRE]

Kinnings SL, Xie L, Fung KH, Jackson RM, Bourne PE. The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol 2010; 6: e1000976 Palomino JC, Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J Antimicrob Chemother 2013; 68: 275-83

Gillespie SH, Crook AM, McHugh TD et al. Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. New England Journal of Medicine 2014 Maitra A, Bates S, Kolvekar T et al. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis. Int J Infect Dis 2015; 32: 50-5

Amaral L, Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int J Antimicrob Agents 2012; 39: 376- 80

Gupta S, Cohen KA, Winglee K et al. Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 2014; 58: 574-576 Maiga M, Ammerman NC, Maiga MC et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis 2013; 208: 512-9

Gold B, Pingle M, Brickner SJ et al. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A 2012; 109: 16004-11 [OpenAIRE]

Guzman JD, Evangelopoulos D, Gupta A et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 2013; 3

17 references, page 1 of 2
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue